Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan's Taisho Falters Under NHI Price Cuts; Eisai Squeezing Sales Out Of Aricept - Japanese Earnings Week

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Taisho Pharmaceutical Co. said it operated in a difficult business environment in 2010, attributing weak sales to National Health Insurance price cuts and decreased demand for cold remedies

You may also be interested in...



Taisho Buys Malaysia's Leading Domestic Pharma To Build Distribution Hub For APAC

TOKYO - Taisho Pharmaceutical Co. Ltd., Japan's largest OTC manufacturer, carved out an entry in Southeast Asia with energy drink series Lipovitan, and now the company is looking to maximize its 2009 acquisition of Bristol-Myers Squibb Co.'s Asian OTC subsidiary through distribution channels from an acquisition of Malaysia's largest domestic pharmaceutical company

Taisho Buys Malaysia's Leading Domestic Pharma To Build Distribution Hub For APAC

TOKYO - Taisho Pharmaceutical Co. Ltd., Japan's largest OTC manufacturer, carved out an entry in Southeast Asia with energy drink series Lipovitan, and now the company is looking to maximize its 2009 acquisition of Bristol-Myers Squibb Co.'s Asian OTC subsidiary through distribution channels from an acquisition of Malaysia's largest domestic pharmaceutical company

Approval Highs And Lows For Leading Japanese Pharma; Dogged By Competitors And Nagging Supply Issues

TOKYO - Japanese pharma Eisai, Daiichi Sankyo and Mitsubishi Tanabe have had a rough seven days despite last week's slate of new drug approvals in Japan. Those approvals were capped with Mitsubishi Tanabe recalls and Eisai's discontinuation of a key Phase III trial

Related Content

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel